Overexpression of CUGBP1 in skeletal muscle from adult classic myotonic dystrophy type 1 but not from myotonic dystrophy type 2

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Cardani, Rosanna ^a   Bugiardini, Enrico ^b   Renna, Laura V ^b   Rossi, Giulia ^c   Colombo, Graziano ^b   Valaperta, Rea ^a   Novelli, Giuseppe ^d   Botta, Annalisa ^c   Meola, Giovanni ^a,b  

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CUGBP1 PROTEIN; MBNL1 PROTEIN; MESSENGER RNA PRECURSOR; RNA; RNA BINDING PROTEIN; UNCLASSIFIED DRUG; ATP2A1 PROTEIN, HUMAN; CELF1 PROTEIN, HUMAN; CHLORIDE CHANNEL; CLC-1 CHANNEL; CNBP PROTEIN, HUMAN; MBNL1 PROTEIN, HUMAN; MESSENGER RNA; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ADULT; AGED; ALTERNATIVE RNA SPLICING; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; CUGBP1 GENE; GENE; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MIDDLE AGED; MUSCLE BIOPSY; MYOTONIC DYSTROPHY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; SKELETAL MUSCLE; YOUNG ADULT; CASE CONTROL STUDY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADULT; AGED; ALTERNATIVE SPLICING; CASE-CONTROL STUDIES; CHLORIDE CHANNELS; GENE EXPRESSION REGULATION; HUMANS; MIDDLE AGED; MUSCLE, SKELETAL; MYOTONIC DYSTROPHY; PHENOTYPE; RNA, MESSENGER; RNA-BINDING PROTEINS; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; YOUNG ADULT;

EID: 84893518233     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083777     Document Type: Article

References (73)

1. Harper PS (2001) Myotonic Dystrophy. W.B. Sanders. 3th edition. London. 106 p.
2. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3′ end of a transcript encoding a protein kinase family member. Cell 69: 799-808.
3. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C, et al. (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′untranslated region of the gene. Science 255: 1253-1255.
4. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, et al. (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293: 864-867. (Pubitemid 32743976)
5. Ranum LP, Cooper TA (2006) RNA-mediated neuromuscular disorders. Annu Rev Neurosci 29: 259-277. (Pubitemid 44476846)
6. Kuyumcu-Martinez NM, Cooper TA (2006) Misregulation of alternative splicing causes pathogenesis in myotonic dystrophy. Prog Mol Subcell Biol 44: 133-159.
7. Osborne RJ, Thornton CA (2006) RNA-dominant diseases. Hum Mol Genet 15: R162-R169. (Pubitemid 44446789)
8. Meola G, Cardani R (2009) RNA binding proteins in myotonic dystrophies. In: Denman RB, editor. RNA binding proteins in development and disease. Kerala: Research Signpost. pp 153-166.
9. Miller JW, Urbinati CR, Teng-umnuay P, Stenberg MG, Byrne BJ, et al. (2000) Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy. EMBO J 19: 4439-4448.
10. Kino Y, Mori D, Oma Y, Takeshita Y, Sasagawa N, et al. (2004) Muscleblind protein, MBNL1/EXP, binds specifically to CHHG repeats. Hum Mol Genet 13: 495-507. (Pubitemid 38313209)
11. Mankodi A, Urbinati CR, Yuan QP, Moxley RT, Sansone V, et al. (2001) Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 10: 2165-2170. (Pubitemid 32998828)
12. Fardaei M, Rogers MT, Thorpe HM, Larkin K, Hamshere MG, et al. (2002) Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 11: 805-814. (Pubitemid 34428648)
13. Fardaei M, Larkin K, Brook JD, Hamshere MG (2001) In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res 29: 2766-2771. (Pubitemid 32685039)
14. Mankodi A, Teng-umnuay P, Krym M, Henderson D, Swanson M, et al. (2003) Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol 54: 760-768. (Pubitemid 37498959)
15. Dansithong W, Paul S, Comai L, Reddy S (2005) MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J Biol Chem 280: 5773-5780. (Pubitemid 40280057)
16. Savkur RS, Philips AV, Cooper TA (2001) Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Gen 29: 40-47. (Pubitemid 32801806)
17. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, et al. (2001) RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 276: 7820-7826.
18. Ashizawa T, Baiget M (2000) New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology 54:1218-221. (Pubitemid 30174036)
19. Schoser B, Timchenko L (2010) Myotonic dystrophies 1 and 2: complex diseases with complex mechanisms. Curr Genomics11: 77-90.
20. Schara U, Schoser BGH (2006) Myotonic Dystrophies type 1 and 2 - a summary of current aspects. Semi Pediatr Neurol 13: 71-79. (Pubitemid 44486821)
21. Machuca-Tzili L, Brook D, Hilton-Jones D (2005) Clinical and molecular aspects of the myotonic dystrophies: a review. Muscle Nerve 32: 1-18. (Pubitemid 40917885)
22. Thornton CA, Griggs RC, Moxley RT 3rd (1994) Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 35: 269-272. (Pubitemid 24089648)
23. Ricker K, Koch MC, Lehmann-Horn F, Pongratz D, Otto M, et al. (1994) Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 44: 1448-1452. (Pubitemid 24247435)
24. Udd B, Krahe R, Wallgren-Pettersson C, Falck B, Kalimo H (1997) Proximal myotonic dystrophy: a family with autosomal dominant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromuscul Disord 4: 217-288.
25. Rotondo G, Sansone V, Cardani R, Mancinelli E, Krahe R. et al. (2005) Proximal myotonic dystrophy mimicking progressive muscular atrophy. Eur J Neurol 12: 160-161. (Pubitemid 40260738)
26. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, et al. (2003) Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 60: 657-664. (Pubitemid 36246086)
27. rd workshop, 14-16 February 2003, Naarden, the Netherlands. Neuromuscul Disord 13: 589-596.
28. Bachinsky LL, Czernuszewicz T, Ramagli LS, Suominen T, Shriver MD, et al. (2009) Premutation allele pool in myotonic dystrophy type 2. Neurology 72: 490-497.
29. Vihola A, Bassez G, Meola G, Zhang S, Haapasalo H, et al. (2003) Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurology 60: 1854-1857. (Pubitemid 36737094)
30. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, et al. (2004) Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 29: 275-281. (Pubitemid 38166851)
31. Ho TH, Bundman D, Armstrong DL, Cooper TA (2005) Transgenic mice expressing CUG-BP1 reproduce splicing mis-regulation observed in myotonic dystrophy. Hum Mol Genet 14: 1539-1547. (Pubitemid 40823462)
32. Mahadevan MS, Yadava RS, Yu Q, Balijepalli S, Frenzel-McCardell CD, et al. (2006) Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 38: 1066-1070. (Pubitemid 44325934)
33. Orengo JP, Ward AJ, Cooper TA (2011) Alternative splicing dysregulation secondary to skeletal muscle regeneration. Ann Neurol 69: 681-690.
34. Salisbury E, Schoser B, Schneider-Gold C, Wang GL, Huichalaf C, et al. (2009) Expression of RNA CCUG repeats dysregulates translation and degradation of proteins in myotonic dystrophy 2 patients. Am J Pathol 175: 748-762.
35. Lin X, Miller JW, Mankodi A, Kanadia RN, Yuan Y, et al. (2006) Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet 15: 2087-2097. (Pubitemid 43923398)
36. Pelletier R, Hamel F, Beaulieu D, Patry L, Haineault C, et al. (2009) Absence of a differentiation defect in muscle satellite cells from DM2 patients. Neurobiol Dis 36: 181-190.
37. Botta A, Caldarola S, Vallo L, Bonifazi E, Fruci D, et al. (2006) Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy II (DM2). Biochem Biophys Acta 1762: 329-334. (Pubitemid 43172848)
38. Margolis JM, Schoser BG, Moseley ML, Day JW, Ranum LPW (2006) DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 15: 1808-1815. (Pubitemid 43821771)
39. Huichalaf C, Schoser B, Schneider-Gold C, Jin B, Sarkar P, et al. (2009) Reduction of the rate of protein translation in patients with myotonic dystrophy 2. J Neurosci 29: 9042-9049.
40. Raheem O, Olufemi SE, Bachinski LL, Vihola A, Sirito M, et al. (2010) Mutant (CCTG)n expansion causes abnormal expression of zinc finger protein 9 (ZNF9) in myotonic dystrophy type 2. Am J Pathol 177: 3025-3036.
41. Moxley 3rd RT, Meola G, Udd B, Ricker K (2002) Report of the 84th ENMC workshop: PROMM (proximal myotonic myopathy) and other myotonic dystrophy-like syndromes: 2nd workshop. 13-15th October 2000, Loosdrecht: The Netherlands. Neuromuscul Disord 12: 306-317. (Pubitemid 34136916)
42. Cardani R, Mancinelli E, Sansone V, Rotondo G, Meola G (2004) Biomolecular identification of (CCTG)n mutation in myotonic dystrophy type 2 (DM2) by FISH on muscle biopsy. Eur J Histochem 48: 437-442.
43. Bonifazi E, Vallo L, Giardina E, Botta A, Novelli G (2004) A long PCR-based molecular protocol for detecting normal and expanded ZNF9 alleles in myotonic dystrophy type 2. Diagn Mol Pathol 13:164-166. (Pubitemid 39121742)
44. Dubowitz V (1985) Muscle biopsy. In: Dubowitz V, editor. A practical approach. Bailliere Tindall, London. Pp 19-40.
45. Massa R, Panico MB, Caldarola S, Fusco FR, Sabatelli P, et al. (2010) The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles. Neuropathol Appl Neurobiol 36: 275-284.
46. Kimura T, Nakamori M, Lueck JD, Pouliquin P, Aoike F, et al. (2005) Altered mRNA splicing of the skeletal muscle ryanodine receptor and sarcoplasmic/endoplasmic reticulum Ca2+-ATPase in myotonic dystrophy type 1. Hum Mol Genet 14: 2189-2200. (Pubitemid 41418018)
47. Botta A, Rinaldi F, Catalli C, Vergani L, Bonifazi E, et al. (2008) The CTG repeat expansion size correlates with the splicing defects observed in muscles from myotonic dystrophy type 1 patients. J Med Genet 45: 639-646.
48. Orengo JP, Chambon P, Metzger D, Mosier DR, Snipes GJ, et al. (2008) Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc Natl Acad Sci 105: 2646-2651. (Pubitemid 351520567)
49. Botta A, Vallo L, Rinaldi F, Bonifazi E, Amati F, et al (2007) Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr 13: 339-351. (Pubitemid 47289407)
50. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
51. Kuyumcu-Martinez NM, Wang GS, Cooper TA (2007) Increased steady-state levels of CUGBP1 in myotonic dystrophy 1 are due to PKC-mediated hyperphosphorylation. Mol Cell 28: 68-78. (Pubitemid 47531966)
52. Salisbury E, Sakai K, Schoser B, Huichalaf C, Schnider-Gold C, et al. (2008) Ectopic expression of cyclin D3 corrects differentiation of DM1 myoblasts through activation of RNA CUG-binding protein, CUGBP1. Exp Cell Res 314: 2266-2278. (Pubitemid 351822334)
53. Hino S, Kondo S, Sekiya H, Saito A, Kanemoto S, et al. (2007) Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1. Hum Mol Genet 16: 2834-2843. (Pubitemid 350048382)
54. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, et al. (2008) A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA 105: 20333-20338.
55. Kino Y, Washizu C, Oma Y, Onishi H, Nezu Y, et al. (2009) MBNL and CELF proteins regulate alternative splicing of the skeletal muscle chloride channel CLCN1. Nucleic Acids Res 37: 6477-6490.
56. Sen S, Talukdar I, Webster NJ (2009) SRp20 and CUG-BP1 modulate insulin receptor exon 11 alternative splicing. Mol Cell Biol 29: 871-880.
57. Sen S, Talukdar I, Liu Y, Tam J, Reddy S, et al. (2010) Muscleblind-like 1 (Mbnl1) promotes insulin receptor exon 11 inclusion via binding to a downstream evolutionarily conserved intronic enhancer. J Biol Chem 285: 25426-25437.
58. Ranum LW, Day JW (2004) Myotonic Dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 74: 793-804.
59. Jacobs AE, Benders AA, Oosterhof A, Veerkamp JH, van Mier P, et al. (1990) The calcium homeostasis and the membrane potential of cultured muscle cells from patients with myotonic dystrophy. Biochim Biophys Acta 1096: 14-19.
60. Bassez G, Chapoy E, Bastuji-Garin S, Radvanyi-Hoffman H, Authier FJ, et al (2008) Type 2 myotonic dystrophy can be predicted by the combination of type 2 muscle fiber central nucleation and scattered atrophy. J Neuropathol Exp Neurol 67:319-325. (Pubitemid 351507487)
61. Pisani V, Panico MB, Terracciano C, Bonifazi E, Meola G, et al (2008) Preferential central nucleation of type 2 myofibers is an invariable feature of myotonic dystrophy type 2. Muscle Nerve 38: 1405-1411.
62. Cardani R, Giagnacovo M, Botta A, Rinaldi F, Morgante A, et al. (2012) Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2. J Neurol 259: 2090-2099.
63. Jiang H, Mankodi A, Swanson MS, Moxley RT, Thornton CA (2004) Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet 13: 3079-3088. (Pubitemid 40045262)
64. Mankodi A, Lin X, Blaxall BC, Swanson MS, Thornton CA (2005) Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res 97: 1152-1155.
65. Gates DP, Coonrod LA, Berglund JA (2011) Autoregulated Splicing of muscleblind-like 1 (MBNL1) Pre-mRNA. J Biol Chem 286: 34224-34233.
66. Timchenko NA, Patel R, Iakova P, Cai ZJ, Quan L, et al (2004) Overexpression of CUG triplet repeatbinding protein, CUGBP1, in mice inhibits myogenesis. J Biol Chem 279: 13129-13139. (Pubitemid 38445891)
67. Ward AJ, Rimer M, Killian JM, Dowling JJ, Cooper TA (2010) CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1. Hum Mol Gen 19: 3614-3622.
68. Kanadia RN, Johnstone KA, Mankodi A, Lungu C, Thornton CA, et al. (2003) A muscleblind knockout model for myotonic dystrophy. Science 302: 1978-1980. (Pubitemid 37523508)
69. Farkas-Bargeton E, Barbet JP, Dancea S, Wherle R, Checouri A, et al. (1988) Immaturity of muscle fibers in the congenital form of myotonic dystrophy: its consequences and its origin. J Neurol Sci 83: 145-159. (Pubitemid 18043008)
70. Sarnat HB, Silbert SW (1976) Maturational arrest of fetal muscle in neonatal myotonic dystrophy. A pathologic study of four cases. Arch Neurol 33: 466-474.
71. Tanabe Y, Nonaka I (1987) Congenital myotonic dystrophy. Changes in muscle pathology with ageing. J Neurol Sci 77: 59-68. (Pubitemid 17207624)
72. -/- mice is associated with multiorgan abnormalities resembling myotonic dystrophy. J Mol Biol 368: 8-17.
73. Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56: 336-340. (Pubitemid 32144144)